mRNA-1010/1011
Seasonal Influenza
Key Facts
About Moderna
Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. Its historic achievement was the rapid development and global commercialization of SPIKEVAX®, a COVID-19 vaccine that proved the platform's efficacy and scalability. The company's strategy leverages its validated mRNA platform, substantial financial resources, and commercial infrastructure to build a durable portfolio of vaccines and therapeutics, aiming to address a wide spectrum of diseases with high unmet need.
View full company profileTherapeutic Areas
Other Seasonal Influenza Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA-based Influenza Vaccine | Sanofi | Phase 3 |
| Standalone Seasonal Influenza Vaccine | Novavax | Phase 3 |
| LUNAR®-FLU (ARCT-2138) | Arcturus Therapeutics | Phase 1 |
| Oral Influenza Vaccine | Vaxart | Phase 2 |